Skip to content

STSF catheter compared with TC and ST catheter applied to atrial tachycardia after persistent atrial fibrillation ablation

STSF catheter compared with TC and ST catheter applied to atrial tachycardia after persistent atrial fibrillation ablation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034907
Enrollment
Unknown
Registered
2020-07-24
Start date
2020-04-02
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation, atrial tachycardia

Interventions

TC:THERMOCOOL (CARTO, Biosense Webster, Diamond Bar, CA, USA) (TC) catheter
ST:THERMOCOOL SMARTTOUCH Catheter (CARTO, Biosense Webster, Diamond Bar, CA, USA) (ST) catheter
STSF:THERMOCOOL SMARTTOUCH SF Catheter (CARTO, Biosense Webster, Diamond Bar, CA, USA) (STSF) catheter

Sponsors

Shanghai Jiao Tong University, Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years old; 2. recurrent persistent atrial tachycardia patients who had undergone persistent atrial fibrillation catheter ablation only once at least 3 months before enrolment; 3. refractoriness to at least one antiarrhythmic drug; 4. left atrial diametrer <=60mm.

Exclusion criteria

Exclusion criteria: 1. With uncontrolled congestive heart failure; 2. Having significant valvular disease and/or prosthetic heart valve(s); 3. With myocardial infarction or stroke within 6 months of screening; 4. With Significant congenital heart disease; 5. Ejection fraction was <40% measured by echocardiography; 6. Allergic to contrast media; 7. Contraindication to warfarin or heparin; 8. Severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive disease (COPD); 9. Left atrial (LA) thrombus measured by pre-procedure transesophageal echocardiography; 10. having any contraindication to right or left sided heart catheterization; 11. Poor general health; 15. Life expectancy less than 6 months.

Design outcomes

Primary

MeasureTime frame
AT termination by ablation;bidirectional block of ablation line;Long-term freedom from recurrent atrial arrhythmias;

Secondary

MeasureTime frame
incidence of complications;improvement in quality of life;

Countries

China

Contacts

Public ContactXu Liu

Shanghai Jiao Tong University, Shanghai Chest Hospital

shchestcardiology@163.com+ 86 21 62821990 2603

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026